Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

por Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M
Publicado 2015

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

por Vadhan-Raj, Saroj, Abonour, Rafat, Goldman, Jonathan W., Smith, David A., Slapak, Christopher A., Ilaria, Robert L., Tiu, Ramon V., Wang, Xuejing, Callies, Sophie, Cox, Joanne, Tuttle, Jay L., Lau, Yiu-Keung, Roeland, Eric J.
Publicado 2017

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

por Simon, George R., Ilaria, Robert L., Sovak, Mika A., Williams, Charles C., Haura, Eric B., Cleverly, Ann L., Sykes, Amanda K., Wagner, Margaret M., de Alwis, Dinesh P., Slapak, Christopher A., Miller, Mary A., Spriggs, David R.
Publicado 2011